Cohance Lifesciences
Cohance Lifesciences Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Cohance Lifesciences Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Cohance Lifesciences Ltd trades at a P/E of 88.61× and P/B of 4.06×.
Valuation
Profitability
Growth
Financial Health
Cohance Lifesciences Ltd chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Cohance Lifesciences Ltd — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Cohance Lifesciences Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Cohance Lifesciences Ltd, switchable between annual and quarterly views, consolidated or standalone.
Cohance Lifesciences Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹15,543.7 Cr and reported EPS of ₹4.67.
| Period | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 834 | 1,010 | 1,320 | 1,340 | 1,051 | 1,198 | 2,269 |
| Other Income | 18 | 14 | 92 | 46 | 62 | 59 | 34 |
| Total Income | 852 | 1,024 | 1,413 | 1,387 | 1,113 | 1,256 | 2,303 |
| Cost of Goods Sold (COGS) | 229 | 302 | 399 | 409 | 315 | 305 | 663 |
| Gross Profit | 605 | 708 | 921 | 931 | 736 | 892 | 1,606 |
| +Operating Expenses | 219 | 267 | 342 | 365 | 331 | 517 | 1,179 |
| EBITDA | 385 | 440 | 579 | 567 | 406 | 375 | 427 |
| +Non-Operating Expenses | 47 | 41 | 45 | 53 | 62 | 90 | 195 |
| Profit Before Tax (PBT) | 356 | 414 | 626 | 560 | 406 | 344 | 207 |
| +Tax Expense | 88 | 105 | 214 | 148 | 105 | 79 | 57 |
| Profit After Tax (PAT) | 317 | 362 | 454 | 411 | 300 | 265 | 150 |
| Earnings Per Share (EPS) | 12.45 | 14.23 | 17.83 | 16.16 | 11.80 | 10.52 | 4.68 |
| Diluted Shares Outstanding (Nos.) | 25 | 25 | 25 | 25 | 25 | 25 | 38 |
| +Additional Disclosures | 772 | 965 | 1,226 | 1,236 | 1,036 | 1,228 | 2,799 |
| Sales Growth % | — | 21.10 | 30.75 | 1.52 | -21.56 | 13.91 | 89.43 |
| YoY Sales Growth % | — | 21.10 | 30.75 | 1.52 | -21.56 | 13.91 | 89.43 |
| Material Cost % | 29 | 31 | 35 | 32 | 25 | 19 | 31 |
| Employee Cost % | 9 | 8 | 8 | 8 | 13 | 21 | 22 |
| Other Cost % | 17 | 19 | 18 | 19 | 19 | 22 | 30 |
| OPM % | 46 | 44 | 44 | 42 | 39 | 31 | 19 |
| Tax % | 25 | 25 | 34 | 27 | 26 | 23 | 27 |
| Profit Growth % | — | 14.30 | 25.24 | -9.37 | -26.99 | -11.83 | -43.30 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 361 | 409 | 540 | 519 | 351 | 298 | 240 |
Cohance Lifesciences segment analysis: revenue and profit mix.
Disclosed business segments at Cohance Lifesciences with their share of revenue and profit, switchable between consolidated and standalone reporting.
Cohance Lifesciences discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Cohance Lifesciences Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Cohance Lifesciences Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Cohance Lifesciences Ltd's investment case rests on 9 positive markers and 11 flagged concerns drawn from the latest reported filings.
What you're getting.
The company maintains a very healthy debt-to-equity ratio of 0.16, indicating strong financial stability and low reliance on borrowed capital, which is positive for long-term sustainability.
Cohance Lifesciences demonstrates a strong operating profit margin (OPM) of 28.80%, highlighting efficient cost management and healthy core business profitability.
Promoters hold a substantial 57.49% stake, reflecting strong confidence in the company's future prospects and aligning management interests with shareholder value creation.
The company reported a decent 12.60% growth in quarterly sales, indicating continued revenue generation and market demand for its products in the recent period.
Domestic Institutional Investors (DIIs) have significantly increased their holding to 20.81% in the latest quarter, showing growing institutional confidence in the company.
What can break it.
With a P/E ratio of 86.10, the stock appears significantly overvalued compared to the industry average and most peers, suggesting high investor expectations that may be difficult to sustain.
The company experienced a substantial -27.50% decline in quarterly profit, raising concerns about recent operational challenges or increased costs impacting profitability.
Cohance's Return on Capital Employed (ROCE) at 14.90% and Return on Equity (ROE) at 12.70% are notably lower than most of its key pharmaceutical peers.
The current price of 786.00 is very close to its 52-week low of 767.00, indicating recent significant downward pressure and investor uncertainty.
Promoter holding has shown volatility, dropping from 66.41% to 57.49% in the last quarter, which could signal inconsistent insider confidence or strategic shifts.
What would change my mind.
Trim if P/E re-rates above 115. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 10.43. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Cohance Lifesciences Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Cohance Lifesciences Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Cohance Lifesciences Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Cohance Lifesciences Ltd — derived from the live tape, not yesterday's close.
Cohance Lifesciences Ltd last traded at ₹405.85 with an intraday range of ₹403.55–₹412.3 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹405.85| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 428.42 | +22.57 | +5.56% |
| R3 | 419.67 | +13.82 | +3.40% |
| R2 | 415.98 | +10.13 | +2.50% |
| R1 | 410.92 | +5.07 | +1.25% |
| PIVOT | 407.23 | 1.38 | 0.34% |
| CURRENT | 405.85 | — | — |
| S1 | 384.67 | -21.18 | -5.22% |
| S2 | 393.42 | -12.43 | -3.06% |
| S3 | 398.48 | -7.37 | -1.82% |
| S4 | 402.17 | -3.68 | -0.91% |
COHANCE is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: 407.1 ~ 412.3
Trading Below opening range, showing Bearishness
Cohance Lifesciences Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Cohance Lifesciences Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Cohance Lifesciences Ltd stood at 60.1% of traded volume, against a 20-day average of 46.1%.
Cohance Lifesciences announcements: results, concalls, ratings, M&A.
Filings Cohance Lifesciences sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Cohance Lifesciences files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 145 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Cohance Lifesciences Limited has informed the Exchange about Schedule of meet
Copy of Newspaper Publication
Cohance Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
Analysts/Institutional Investor Meet/Con. Call Updates
Cohance Lifesciences Limited has informed the Exchange about Schedule of meet
Price movement
Significant movement in price has been observed in Cohance Lifesciences Limited. The Exchange, in order to ensure that investors have latest relevant…
Price movement
Significant movement in price has been observed in Cohance Lifesciences Limited. The Exchange, in order to ensure that investors have latest relevant…
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Cohance Lifesciences insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Cohance Lifesciences as reported to SEBI — buying and selling signals from the people who know the business best.
Cohance Lifesciences insider activity below tracks 2 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Jusmiral Holdings Limited | Insider | 09 May 2025 | buy | +12.65 Cr | ₹12.65 Cr | ₹1.00 |
| Dr. Venkata Naga Kali Vara Prasada Raju Vetukuri | Insider | 09 May 2025 | buy | +7.13 L | ₹7.13 L | ₹1.00 |
Cohance Lifesciences dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Cohance Lifesciences has declared, sequenced by announce and record date.
Cohance Lifesciences corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Cohance Lifesciences Ltd: business, sector, key facts.
What Cohance Lifesciences Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Cohance Lifesciences Ltd operates in the Healthcare, listed as NSE: COHANCE, BSE: 543064.
Cohance Lifesciences Limited is an Indian contract development and manufacturing organization (CDMO) specializing in the pharmaceutical industry. Their core business revolves around providing comprehensive services throughout the entire drug development and manufacturing process, from the initial stages of creating intermediate compounds and active pharmaceutical ingredients (APIs) to the final production of finished dosage formulations (FDFs).
A significant portion of Cohance's business is centered around its CDMO services. This encompasses offering flexible and customized solutions designed to meet the unique and often complex development and manufacturing requirements of its clients. They cater to companies needing assistance with various aspects of drug production, allowing for tailored approaches to challenges encountered during the drug lifecycle.
Beyond CDMO services, Cohance produces and supplies APIs and FDFs for a wide range of pharmaceutical applications. This direct manufacturing capability complements their CDMO services, offering clients a complete spectrum of pharmaceutical production capabilities, from basic building blocks to final consumer-ready products. Their API offerings extend beyond pharmaceuticals; they also manufacture specialty chemicals, such as those used in the electronics industry.
Supporting their core manufacturing and development functions, Cohance provides a suite of analytical, clinical, and research services. These services likely support internal processes as well as offer additional services to clients, furthering their role as a comprehensive partner for pharmaceutical development. The integrated nature of these services underlines their commitment to a holistic approach in servicing the pharmaceutical industry.
Established in 1989 and based in Hyderabad, India, Cohance (formerly Suven Pharmaceuticals Limited) is a subsidiary of Berhyanda Limited. The company's long history and presence in India's pharmaceutical sector positions it as a significant player in the global CDMO landscape. Their diverse offerings and commitment to customized solutions underscore their efforts to cater to the evolving needs of the pharmaceutical market.
Questions investors ask about Cohance Lifesciences Ltd (COHANCE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Cohance Lifesciences Ltd (COHANCE)?
The current share price of Cohance Lifesciences Ltd (COHANCE) is ₹405.85. Today, the stock has declined by ₹7.95 (1.92%), trading in a range of ₹403.55 to ₹412.3. The stock opened at ₹410 with a trading volume of 7,77,587 shares.
02Is Cohance Lifesciences Ltd stock a good investment for long-term?
Cohance Lifesciences Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹15,543.7 crores, P/E ratio of 88.61, ROE of 3.84%, and ROCE of 14.90%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Cohance Lifesciences Ltd stock?
The 52-week high price of Cohance Lifesciences Ltd (COHANCE) is ₹1,121.15, while the 52-week low is ₹266.7. Currently trading at ₹405.85, the stock is 16.3% away from its 52-week low and 63.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Cohance Lifesciences Ltd stock at the current price?
Whether to buy Cohance Lifesciences Ltd stock at ₹405.85 depends on multiple factors. The stock is currently trading with a P/E ratio of 88.61 and P/B ratio of 4.06. Today's performance shows a loss of 1.92%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Cohance Lifesciences Ltd and when is the next dividend?
Cohance Lifesciences Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹405.85, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd's key financial metrics include: P/E Ratio: 88.61, P/B Ratio: 4.06, ROE: 3.84%, ROCE: 14.90%, Dividend Yield: 0.00%, EPS: ₹4.67, Book Value: ₹102.03, and Debt-to-Equity: 9.93. The company's market cap stands at ₹15,543.7 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Cohance Lifesciences Ltd stock performing today in the market?
Cohance Lifesciences Ltd stock opened at ₹410 and is currently trading at ₹405.85, showing a decline of ₹7.95 (1.92%). The intraday high is ₹412.3 and low is ₹403.55. The trading volume stands at 7,77,587 shares, indicating moderate market participation today.
08What is the P/E ratio of Cohance Lifesciences Ltd and what does it indicate?
Cohance Lifesciences Ltd has a Price-to-Earnings (P/E) ratio of 88.61, which means investors are willing to pay ₹88.61 for every ₹1 of earnings. With an EPS of ₹4.67, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Cohance Lifesciences Ltd (COHANCE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy